BCL9L antibody (N-Term)

Catalog No. ABIN6991496

The Rabbit Polyclonal anti-BCL9L antibody has been validated for WB, ELISA, ICC, IF and IHC (p). It is suitable to detect BCL9L in samples from Human.

Quick Overview for BCL9L antibody (N-Term) (ABIN6991496)

Target: BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This BCL9L antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunocytochemistry (ICC), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-BCL9L Antibody

Binding Specificity: AA 20-70, N-Term

Specificity: Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist, this antibody will detect all four.

Purification: Bcl9L Antibody is affinity chromatography purified via peptide column.

Immunogen: Bcl9L antibody was raised against a 20 amino acid synthetic peptide near the amino terminus of human Bcl9L. The immunogen is located within amino acids 20 - 70 of Bcl9L.

Isotype: IgG

Application Details

Application Notes: Bcl9L antibody can be used for detection of Bcl9L by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL and immunocytochemistry starting at 10 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.

Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples, Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: Bcl9L Antibody is supplied in PBS containing 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,4 °C

Storage Comment: Bcl9L antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Target Details for BCL9L

Target: BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))

Alternative Name: Bcl9L

Background: Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

Molecular Weight: Predicted: 165 kDa

Observed: 195 kDa

Gene ID: 283149

NCBI Accession: NP_872363

UniProt: Q86UU0

Pathways: Stem Cell Maintenance